Yüklüyor......
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
Mogamulizumab-kpkc provides a novel mechanism of action for the treatment of mycosis fungoides and Sézary syndrome. The efficacy and safety of mogamulizumab-kpkc for the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome were demonstrated in a multicenter, open-label, randomiz...
Kaydedildi:
| Yayımlandı: | J Adv Pract Oncol |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Harborside Press LLC
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7517756/ https://ncbi.nlm.nih.gov/pubmed/33425472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.8.10 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|